The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)
GR Bernard, Jean‐Louis Vincent(Université Libre de Bruxelles), JS Steingrub, SP LaRosa, Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), CJ Fisher, Dhainaut Jf, E. Wesley Ely(Vanderbilt University Medical Center), Jeffrey D. Helterbrand, Angel Lopez-Rodriguez, Gary Garber(University of Ottawa)
Cited by 213
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k